^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Pancreatic Adenocarcinoma

    Related cancers:
    1d
    PHOLIPANC: Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, The University of Texas Health Science Center at San Antonio | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)
    2d
    PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer (clinicaltrials.gov)
    P2, N=20, Terminated, Cancer Trials Ireland | Trial completion date: Jun 2026 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2025 --> Mar 2026; Study terminated due to futility
    Trial completion date • Trial termination • Trial primary completion date
    |
    Mekinist (trametinib) • hydroxychloroquine
    2d
    FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, Colin D. Weekes, M.D., PhD | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • elraglusib (9-ING-41)
    2d
    The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Nuvance Health | Trial completion date: Apr 2027 --> Apr 2030 | Trial primary completion date: Apr 2025 --> Apr 2030
    Trial completion date • Trial primary completion date
    3d
    Pan-cancer analysis reveals FOLH1 as a prognostic biomarker and immune modulator in human tumors. (PubMed, Transl Cancer Res)
    FOLH1 may be involved in tumor progression by regulating amino acid metabolic pathways and the immune microenvironment. It is a promising pan-cancer prognostic marker and synergistic target for immunotherapy.
    Journal • Tumor mutational burden • BRCA Biomarker • IO biomarker • Pan tumor
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • BRCA (Breast cancer early onset) • FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    7d
    Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy (clinicaltrials.gov)
    P=N/A, N=420, Completed, National Cancer Center, Korea | Active, not recruiting --> Completed
    Trial completion • Liquid biopsy
    |
    KRAS (KRAS proto-oncogene GTPase)
    7d
    Exosomal miR-92a-3p promotes pancreatic cancer cells' extravasation by inducing vascular permeability through inhibition of DAB2IP. (PubMed, Cell Death Dis)
    This activation attenuates expression of intracellular junction markers and stimulates endothelial nitric oxide synthase, leading to increased vascular permeability. Our findings suggest that targeting miR-92a-3p could represent a potential strategy to reduce metastasis in PAAD.
    Journal
    |
    DAB2IP (DAB2 Interacting Protein)
    7d
    ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=150, Active, not recruiting, BAIYONG SHEN | Enrolling by invitation --> Active, not recruiting | Trial completion date: Nov 2025 --> Aug 2028 | Trial primary completion date: Nov 2025 --> Jan 2028
    Enrollment closed • Trial completion date • Trial primary completion date • Minimal residual disease • Circulating tumor DNA
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    8d
    UroPanc: Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers (clinicaltrials.gov)
    P=N/A, N=3500, Active, not recruiting, Queen Mary University of London | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CA 19-9 (Cancer antigen 19-9)
    9d
    LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy (clinicaltrials.gov)
    P1/2, N=12, Completed, Georgetown University | N=44 --> 12 | Active, not recruiting --> Completed
    Trial completion • Enrollment change
    |
    everolimus • Kisqali (ribociclib)
    9d
    Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=10, Recruiting, Northwell Health | Not yet recruiting --> Recruiting
    Enrollment open
    |
    albumin-bound paclitaxel
    10d
    the HOPE trial: Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1, N=34, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Dec 2026 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Mektovi (binimetinib) • hydroxychloroquine